evidence card · opioids_chronic_low_back_pain
Opioids are effective first-line therapy for chronic low back pain
Established consensus
H5
▽ contradicts
stakes high
1 post scored
·
across 1 account
·
6 sources
Summary
High-quality RCTs and systematic reviews show opioids provide only small, short-term pain relief in low back pain with no meaningful functional benefit versus non-opioid analgesics, while carrying substantial risks of dependence, misuse, and overdose. The landmark SPACE trial (Krebs 2018) found opioids were not superior to non-opioid therapy for chronic back/hip/knee pain over 12 months. Consequently, CDC (2022), ACP, NICE (NG59), and WHO guidelines recommend against opioids as first-line therapy for low back pain; NSAIDs, exercise, and multimodal non-pharmacologic care are preferred.
Five-score assessment
Consensus
5/5
CDC (2022), ACP (2017), NICE NG59, and WHO all advise against opioids as first-line therapy for low back pain.
Evidence certainty
5/5
Evidence comes from multiple well-conducted placebo-controlled RCTs (SPACE, OPAL) and Cochrane systematic reviews with low risk of bias and consistent findings.
Replication
5/5
SPACE, OPAL, and the Cochrane meta-analysis independently converge on minimal benefit and substantial harm across acute and chronic presentations.
Contradiction
0/5
none — no credible guideline or high-quality trial supports opioids as effective first-line therapy for low back pain.
Directness
5/5
Outcomes are patient-important: pain, function, misuse, overdose, and mortality — directly actionable in clinical practice.
Scope
Population
Adults with acute, subacute, or chronic non-cancer low back pain
Intervention
Opioid analgesics (short- or long-term)
Outcome
Pain reduction, function, quality of life, and harms (dependence, overdose, misuse)
Not supported for
- Active cancer pain
- End-of-life/palliative care
- Acute post-surgical pain management
Evidence sources
Contradicting (6)
-
12-month RCT found opioid therapy was not superior to non-opioid medication for pain-related function in chronic back/hip/knee pain, with more adverse effects.
-
Meta-analysis of RCTs found only small short-term analgesic effects of opioids vs placebo with no evidence supporting long-term benefit and high dropout from adverse events.
-
RCT of opioids vs placebo for acute low back/neck pain found no benefit on pain at 6 weeks and worse outcomes at 1 year including higher misuse risk.
-
Recommends non-opioid therapies as preferred for subacute and chronic pain including low back pain, given limited benefit and serious harms of opioids.
-
Recommends against offering opioids for chronic low back pain and advises against routine use for acute low back pain.
-
Recommends opioids only as last-line therapy for chronic low back pain after non-pharmacologic and non-opioid options have failed, with risk-benefit discussion.